The Medical Affairs Hematology Oncology Clinical Nurse Educator, Medical Affairs is responsible for the identification and engagement of a targeted group of healthcare professionals (HCPs), including physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other members of multidisciplinary oncology care teams. This position provides consistent delivery of educational and compliant scientific and clinical information in support of Karyopharm’s products and pipeline.
This role will focus on education related to selinexor’s clinical profile, with an emphasis on safety, tolerability, monitoring, adverse event recognition, and supportive care considerations. The Nurse Educator will serve as a clinically credible Medical Affairs representative to care teams and will support appropriate scientific exchange, practical education, and insight generation in support of Medical Affairs launch readiness, scientific exchange and external education planning.
The Clinical Nurse Educator will operate in a non-promotional capacity and will utilize approved resources to address medical education needs, ensuring all activities are compliant with Karyopharm policies and applicable laws, regulations, and industry guidelines.
RESPONSIBILITIES:
R
QUALIFICATIONS:
At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $175K - $195K USD.
This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.
Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.
As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.
Learn more at Karyopharm Therapeutics.
Software Powered by iCIMS
www.icims.com